Open access
Oct 2026
Isobavachalcone targets deubiquitinase OTUB1 to induce PD-L1 degradation and enhances antitumor immunity.
Findings highlight isobavachalcone (IBC) as a potential drug candidate that promotes PD-L1 degradation and demonstrate the therapeutic potential of targeting the OTUB1-PD-L1 axis to improve immune checkpoint therapy.
Qing Zhang, Si-Meng Li, Meng-Ting Xu et al.
· Cell Reports Medicine · 0 citations